Lymph-vascular Space Invasion As a Significant Risk Factor for Isolated Para-aortic Lymph Node Metastasis in Endometrial Cancer: a Study of 203 Consecutive Patients
Overview
Authors
Affiliations
Background: The purpose of this study was to investigate various pathologic risk factors associated with para-aortic lymph node metastasis (LNM) in surgically staged patients with endometrial cancer.
Materials And Methods: We performed a retrospective analysis of 203 consecutive patients with endometrial cancer who were surgically staged from 2000 to 2009. The association among the various pathologic variables for para-aortic LNM was determined with univariate and multivariate analyses.
Results: Of 203 patients, 29 patients (14.3%) had LNM. Also, 10 patients (4.9%) had only pelvic LNM, 14 (6.9%) had both pelvic and para-aortic LNM, and 5 (2.5%) had para-aortic LNM without pelvic LN involvements. Histologic type (P = .001), tumor grade (P < .001), tumor size (P = .003), depth of myometrial invasion (P < .001), cervical invasion (P < .001), parametrial invasion (P = .002), lymph-vascular space invasion (LVSI) (P < .001), serosal/adnexal invasion (P < .001), positive cytology (P = .002), peritoneal seeding (P < .001), and pelvic LNM (P < .001) were significant pathologic factors for para-aortic LNM. On multivariate analysis, cervical invasion (P = .032), LVSI (P = .018), and positive pelvic LNs (P = .002) were independent factors for para-aortic LNM. With regard to isolated para-aortic LNM, tumor grade (P = .017) and LVSI (P = .002) were significant factors for LN involvements. On multivariate analysis, LVSI (P = .004) was the only significant independent factor.
Conclusions: LVSI correlates significantly with the risk of isolated para-aortic LNM in endometrial cancer patients.
Han L, Chen Y, Zheng A, Tan X, Chen H Front Oncol. 2024; 14:1490347.
PMID: 39544303 PMC: 11561408. DOI: 10.3389/fonc.2024.1490347.
Buechi C, Siegenthaler F, Sahli L, Papadia A, Saner F, Mohr S Cancers (Basel). 2024; 16(1).
PMID: 38201495 PMC: 10778553. DOI: 10.3390/cancers16010067.
Lee S, Kang H, Kwak Y, Kim M, Kim J Strahlenther Onkol. 2023; 199(9):828-837.
PMID: 36930247 DOI: 10.1007/s00066-023-02061-1.
Navarro B, Margioula-Siarkou C, Petousis S, Floquet A, Babin G, Guyon F Oncol Lett. 2023; 25(3):122.
PMID: 36844624 PMC: 9950339. DOI: 10.3892/ol.2023.13708.
Jin X, Shen C, Yang X, Yu Y, Wang J, Che X Front Oncol. 2022; 12:881850.
PMID: 35719999 PMC: 9201106. DOI: 10.3389/fonc.2022.881850.